This Week in The Roadhouse Pharmacy
THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.
First SphygmoCor sales in China
AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, has received its first order for SphygmoCor XCEL systems from its Chinese distributor, Angy (China) Medical Ltd.
READ MORE…
Cochlear to launch Implant Series in Europe
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions is to launch the Cochlear™ Nucleus® Profile™ Series across Europe in June.
READ MORE…
Prima BioMed announces CVac trial results
Prima BioMed (ASX: PRR) has claimed CVac has demonstrated a positive trend in overall survival (OS) over standard of care in second remission ovarian cancer patients in the CAN-003 protocol.
READ MORE…
Neuren Pharmaceuticals receives Notice of Allowance of new US patent
Neuren Pharmaceuticals (ASX: NEU) has been issued a Notice of Allowance by the US Patent and Trademark Office for a new patent covering the company’s second drug candidate, NNZ-2591, titled “Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals”.
READ MORE…
Alchemia updates Phase III Trial timeline
Alchemia Limited (ASX: ACL) announced it expects to report the top-line results from a Phase III trial of HA-Irinotecan in metastatic colorectal cancer (mCRC) before the end of the third quarter of CY 2014.
READ MORE…